Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)
Clinical trial NCT02089685 · COMPLETED
Trial details
- NCT number
- NCT02089685
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-03-17
- Primary completion
- 2021-04-01
- Enrollment
- 295
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.